CURE

Calendar of CURE/Yale BioHaven seminars for Fall 2010 now available. more

9/14
8:45 am - 6:00 pm
Ubifrance, the French Agency for international business development, cordially invites CURE members to this year's second French Biotech Tour, which aims to connect French and American Biotech companies specialized in neuroscience, inflammation, and auto-immune diseases. Philadelphia, PA. more

9/16
6:00 pm - 7:30 pm
CURE/Yale BioHaven presents Al Mann: 'Creating a successful medical device enterprise.' Hope Auditorium, Yale University, 315 Cedar Street, New Haven. more

10/5
Deadline for nominations for the Lemelson-MIT prize, awarded to an outstanding mid-career inventor who has developed a patented product or process of significant value to society. more

10/14
4:00 pm - 7:00 pm
Hartford Hospital Research Symposium. 'Personalized Medicine and Genomics: The Future is Now.' RSVP by 10/1 to 860.545.5620. Heublein Hall, Education & Resource Center, Hartford Hospital, Hudson Street, Hartford. more

10/27
4:00 pm - 6:00 pm
CURE/Yale BioHaven presents Cobalt Therapeutics. Anlyan Center, Yale University, 300 Cedar Street, New Haven. more

11/18
4:00 pm - 6:00 pm
CURE/Yale BioHaven presents Biodel Inc. Anlyan Center, Yale University, 300 Cedar Street, New Haven. more

12/7
5:30 pm - 7:30 pm
CURE Holiday Party. Café George, 300 George Street, New Haven. Watch for details.

Artificial Cell Technologies, Inc.
5 Science Park
Suite 13
New Haven, CT 06511

Phone: 203 772 3430
Fax: 203 567 8073
Website: http://www.artificialcelltech.com/

General Information
Artificial Cell Technologies, Inc. is an early-stage biomedical nanotechnology company founded in 2002 to commercialize applications of a new proprietary technology platform involving designed polypeptides.

Our long term vision is to commercialize biotechnology applications for successively more sophisticated versions of an artificial bionanomachine: the artificial cell. ACT was founded to achieve this artificial cell vision by commercializing biomedical applications of our proprietary polypeptide nanostructure technology platform, starting with one of the simplest of human cells, the red blood cell.

ACT?s technology platform includes proprietary methods for manufacturing custom-designed polypeptide films and microcapsules with controlled, tunable biological, chemical, and physical properties.